Precision Oncology News

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Apr 04, 2019

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

To read the full story....

Breaking News

NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths at AACR Annual Meeting

AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

Featured White Papers

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

What's Popular?

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Sponsorships